Study Identifies Resistance of Indian HIV Strains to Certain Broadly Neutralising Antibodies
A study published in the Journal of Virology by researchers at the Translational Health Science and Technology Institute (THSTI) has found that Indian strains of HIV-1 show varying resistance to broadly neutralising antibodies (bNAbs). While these strains were effectively neutralized by bNAbs targeting the V3 glycan on the viral spike protein, they resisted antibodies aimed at the V1/V2 apex. This research highlights the challenge posed by the high genetic diversity of HIV in India and suggests that region-specific antibody cocktails may be necessary for effective prevention and treatment strategies.
Key Points
- Indian HIV-1 strains are sensitive to bNAbs targeting the V3 glycan but resist V1/V2 apex-targeting antibodies.
- The genetic diversity of HIV makes it difficult for a single bNAb to neutralize all variants.
- Researchers propose using a three-antibody cocktail (BG18, N6, PGDM1400) to overcome resistance.
- The study emphasizes the need for region-specific HIV prevention and vaccine strategies.
Exam Facts
- Translational Health Science and Technology Institute (THSTI)
- Journal of Virology
- V3 glycan and V1/V2 apex (viral protein targets)
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.